Gene therapy for HAE: does it last? new study tracks Long-Term safety
NCT ID NCT06262399
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study follows about 100 people with hereditary angioedema who previously received the gene-editing therapy NTLA-2002. Researchers will monitor side effects and how well the treatment controls swelling attacks over time. The goal is to understand if a single dose can provide lasting relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NTLA-2002 (a gene-editing therapy)
What this could lead to
If successful, this could show that a single dose of NTLA-2002 safely reduces or prevents HAE attacks over many years, pointing toward a long-term treatment.
What could go wrong
This is an observational follow-up, not a new treatment test. It may reveal side effects or waning effectiveness over time. The therapy is still experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
Cambridge, United Kingdom
-
Campbelltown Hospital
Campbelltown, New South Wales, 2560, Australia
-
Centre National de Reference - Grenoble
Grenoble, France
-
Charite-Universitätsmedizin Berlin
Berlin, 12203, Germany
-
Hôpital Claude Huriez
Lille, 59037, France
-
New Zealand Clinical Research
Auckland, New Zealand
-
University of Amsterdam Academic Medical Center
Amsterdam, Netherlands